COMPARE · Reviewed August 3, 2026
DOCS vs HNGE
Verdict: Side-by-side breakdown using the Bull Rankings model. DOCS scored 90.6, HNGE scored 72.0 — DOCS leads.
Compare another set
DOCS
Doximity, Inc.
90.6
$21.66 · $3.9B
fundamentals as of
Score gap
18.6
DOCS leads
HNGE
Hinge Health, Inc.
72
$77.65 · $6.0B
fundamentals as of
The model, pillar by pillar (0–100 each)
DOCS
stronger →← stronger
HNGE
90
Qualityreturns · margins · balance sheet
62
93
Growthrevenue & earnings expansion
100
89
Valuevaluation vs sector peers
60
DOCS is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
DOCS
HNGE
$326mC
FCF
$209mC
+13.1%B+
Rev
+49.8%A
0.01A
D/E
0.02A-
22.1xB+
P/E
—
0.59A-
PEG
—
—
P/S
9.3xC+
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
DOCS
HNGE
21% below
Price vs fair valuelower is cheaper
23% above
~2%/yr
Growth the price implies10-yr FCF · lower = less priced in
~20%/yr
+14%
1-yr DCF upside
-38%
+27%
5-yr DCF upside
-18%
+46%
10-yr DCF upside
+22%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
DOCS
Why this score
- Durable high returns
HNGE
Why this score
- Short track record
The companies
DOCSDoximity, Inc.
Why now
Health Information Services · market cap $3.9b. Down 72% from 52-week high of $76.51 — deep drawdown territory. Revenue growing +13%, comfortably above the S&P median. PEG 0.59 — paying under fair value for the growth rate. 18 sell-side analysts rate this a Buy with a mean 1-yr target of $24.61 (implying +14% upside).
Moat
Net margin 30% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 21% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 166% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Down 72% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
HNGEHinge Health, Inc.
Why now
Health Information Services · market cap $6.0b. 15% off the 52-week high of $91.50. Revenue growing +50% — in hypergrowth territory. 15 sell-side analysts rate this a Buy with a mean 1-yr target of $92.67 (implying +19% upside).
Moat
Turnaround / out-of-favor name — GAAP-unprofitable for now, so the durability case is forward-looking: it rests on a recovery (margin normalization, a cyclical upturn or restructuring) or an un-monetized asset (IP / network effects / first-mover position) rather than on current reported results.
Risk
Currently unprofitable (margin -78.9%) — path to GAAP profitability is the core thesis risk. ROE -457% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.